Stock RLMD RELMADA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Relmada Therapeutics, Inc.

Equities

RLMD

US75955J4022

Delayed Nasdaq
Other stock markets
 01:19:46 11/05/2024 am IST 		5-day change 1st Jan Change
3.585 USD -5.66% Intraday chart for Relmada Therapeutics, Inc. -2.17% -13.04%
08/05 Transcript : Relmada Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024
08/05 Relmada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
PR
Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
PR
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
AQ
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024
PR
Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
PR
Relmada Therapeutics Provides Corporate Update
PR
Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023
PR
Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS, Neuro Summit
AQ
Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology Congress
AQ
Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit
PR
Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress
PR
Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder
PR
Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder
PR
Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
PR
Relmada Therapeutics to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 8, 2023
PR
RLMD NOTICE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors With Losses to Inquire About Securities Class Action Investigation - RLMD
PR
Relmada Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference
PR
Relmada Therapeutics to Participate in the 2023 Jefferies Global Healthcare Conference
AQ
ROSEN, A LEADING LAW FIRM, Encourages Relmada Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - RLMD
PR
Relmada Therapeutics to Participate in the 2023 Jefferies Global Healthcare Conference
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RLMD Stock
  4. News Relmada Therapeutics, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW